pyrazines has been researched along with cx 4945 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adami, F; Brancalion, A; Cabrelle, A; Cappellesso, R; Colpo, A; Di Maggio, SA; Gurrieri, C; Mandato, E; Manni, S; Marino, F; Piazza, F; Pizzi, M; Semenzato, G; Trentin, L; Tubi, LQ; Zaffino, F; Zambello, R | 1 |
1 other study(ies) available for pyrazines and cx 4945
| Article | Year |
|---|---|
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Topics: Adenosine Triphosphate; Analysis of Variance; Apoptosis; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Casein Kinase II; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Molecular Sequence Data; Multiple Myeloma; Naphthyridines; NF-kappa B; Phenazines; Pyrazines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor | 2013 |